PDF herunterladen
Thromb Haemost 2006; 95(03): 434-440
DOI: 10.1160/TH05-05-0375
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

The procoagulant effects of factor V Leiden may be balanced against decreased levels of factor V and do not reflect in vivo thrombin formation in newborns

Satu Hyytiäinen
1   Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
,
Ulla Wartiovaara-Kautto
2   Helsinki University Central Hospital Laboratory Services (HUSLAB), Department of Clinical Chemistry, Laboratory of Hematology, University of Helsinki, Helsinki, Finland
,
Veli-Matti Ulander
3   Hospital for Women, University of Helsinki, Helsinki, Finland
,
Risto Kaaja
3   Hospital for Women, University of Helsinki, Helsinki, Finland
,
Markku Heikinheimo
1   Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
4   Department of Pediatrics, University and University Hospital of Tampere, Finland
5   Department of Pediatrics, Washington University School of Medicine, St. Louis, Missouri, USA
,
Jari Petäjä
1   Hospital for Children and Adolescents, University of Helsinki, Helsinki, Finland
6   Department of Pediatrics, Jorvi Hospital, University of Helsinki, Espoo, Finland
› InstitutsangabenFinancial support: This study was supported by the Finnish Pediatric Research Foundation, Helsinki University Hospital Research Funds, and the Juselius Foundation.
Weitere Informationen

Publikationsverlauf

Received 30. Mai 2005

Accepted after resubmission 17. Januar 2006

Publikationsdatum:
29. November 2017 (online)

Auch verfügbar auf
    Lizenzen und Reprints

Summary

Thrombin regulation in newborns remains incompletely understood.We studied tissue factor-initiated thrombin formation in cord plasma in vitro, and the effects of Factor VLeiden (FVL) heterozygosity on thrombin regulation both in vitro and in vivo in newborns. Pregnant women with known thrombophilia (n=27) were enrolled in the study. Cord blood and venous blood at the age of 14 days were collected from 11 FVL heterozygous newborns (FVL-positive) and from 16 FVL-negative newborns. Prothrombin fragment F1+2 and coagulation factors were measured. Tissue factor-initiated thrombin formation was studied in cord platelet-poor plasma (PPP) of FVL-negative and -positive newborns, and in both PPP and platelet-rich plasma (PRP) of healthy controls. The endogenous thrombin potential (ETP) in cord PPP or PRP was ∼60% of that in adult plasma, while thrombin formation started ∼55% and ∼40% earlier in cord PPP and PRP, respectively. Further, in FVL-positive newborns thrombin formation started significantly earlier than in FVL-negative newborns. Exogenous activated protein C (APC) decreased ETP significantly more in cord than in adult PRP. In FVL-negative cord plasma 5nM APC decreased ETP by 17.4±3.5% (mean±SEM) compared with only 3.5±3.8% in FVL-positive cord plasma (p=0.01). FVL-positive newborns showed similar levels of F1+2 but significantly decreased levels of factor V compared with FVL negative newborns both in cord plasma (FV 0.82±0.07 U/ml vs. 0.98±0.05 U/ml, p=0.03) and at the age of two weeks (FV 1.15±0.04 U/ml vs. 1.32±0.05 U/ml, p=0.03). In conclusion, newborn plasma showed more rapid thrombin formation and enhanced sensitivity to APC compared with adult plasma. FVL conveyed APC resistance and a procoagulant effect in newborn plasma. Lack of elevated F1+2 levels in FVL-positive infants, however, suggested the existence of balancing mechanisms; one could be the observed lower level of factor V in FVL heterozygous newborns.

Keywords

Newborn - thrombin - activated protein C - factor V Leiden - platelet-rich plasma
 

  • References

  • 1 Andrew M, Paes B, Milner R. et al. Development of the human coagulation system in the full term infant. Blood 1987; 70: 165-72.
    PubMedGoogle Scholar
  • 2 Andrew M, Paes B, Johnston M. Development of the human coagulation system in the neonate and young infant. Am J Pediatr Hematol Oncol 1990; 12: 95-104.
    CrossrefPubMedGoogle Scholar
  • 3 Yuen PMP, Yin JA, Lao TTH. FibrinopeptideA levels in maternal and newborn plasma. Eur J Obstet Gynecol Reprod Biol 1989; 30: 239-44.
    CrossrefPubMedGoogle Scholar
  • 4 Schneider DM, von Tempelhoff GF, Herrle B. et al. Maternal and cord blood hemostasis at delivery. J Perinat Med 1997; 25: 55-61.
    CrossrefPubMedGoogle Scholar
  • 5 Suarez CR, Walenga J, Mangogna LC. et al. Neonatal and maternal fibrinolysis: activation at time of birth. AmJ Hematol 1985; 19: 365-72.
    PubMedGoogle Scholar
  • 6 Lao TTH, Yin JA, Yuen PMP. Coagulation and anticoagulation systems in newborns - correlation with their mothers at delivery. Gynecol Obstet Invest 1990; 29: 181-4.
    CrossrefPubMedGoogle Scholar
  • 7 Bertina RM, Koeleman BP, Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994; 343: 64-7.
    PubMedGoogle Scholar
  • 8 Koster T, Rosendaal FR, de Ronde H. et al. Venous thromboembolism due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-6.
    CrossrefPubMedGoogle Scholar
  • 9 Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
    CrossrefPubMedGoogle Scholar
  • 10 Dahlbäck B. The discovery of activated protein C resistance. J Thromb Haemost 2003; 01: 3-9.
    CrossrefPubMedGoogle Scholar
  • 11 Nicolaes GAF, Dahlbäck B. Factor V and thrombotic disease. Description of a janus-faced protein. Arterioscler Thromb Vasc Biol 2002; 22: 530-8.
    PubMedGoogle Scholar
  • 12 Castoldi E, Rosing J. Factor V Leiden: a disorder of factor V anticoagulant function. Curr Opin Hematol 2004; 11: 176-81.
    CrossrefPubMedGoogle Scholar
  • 13 Andrew M, David M, Adams M. et al. Venous thromboembolic complications (VTE) in children: First analysis of the Canadian registry of VTE. Blood 1994; 83: 1251-7.
    PubMedGoogle Scholar
  • 14 Hagstrom JN, Walter J, Bluebond-Langner R. et al. Prevalence of the factor V Leiden mutation in children and neonates with thromboembolic disease. J Pediatr 1998; 133: 777-81.
    CrossrefPubMedGoogle Scholar
  • 15 Petäjä J, Hiltunen L, Fellman V. Increased risk of intraventricular hemorrhage in newborn infants with thrombophilia. Pediatr Res 2001; 49: 643-6.
    CrossrefPubMedGoogle Scholar
  • 16 Schmidt B, Ofusu FA, Mitchell L. et al. Anticoagulant effects of heparin in neonatal plasma. Pediatr Res 1989; 25: 405-8.
    CrossrefPubMedGoogle Scholar
  • 17 Andrew M, Schmidt B, Mitchell L. et al. Thrombin generation in newborn plasma is critically dependent of the concentration of prothrombin. Thromb Haemost 1990; 63: 27-30.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 18 Cvirn G, Gallistl S, Leschnik B. et al. Low tissue factor pathway inhibitor (TFPI) together with low antithrombin allows sufficient thrombin generation in neonates. J Thromb Haemost 2003; 01: 263-8.
    CrossrefPubMedGoogle Scholar
  • 19 Petäjä J, Fernandéz JA, Fellman V. et al. Upregulation of the antithrombotic proteinC pathway at birth. Pediatr Hematol Oncol 1998; 15: 489-99.
    CrossrefPubMedGoogle Scholar
  • 20 Schwartz HP, Muntean W, Wazke H. et al. Low total proteinS antigen but high proteinS activity due to decreased C4b-binding protein in neonates. Blood 1988; 71: 562-5.
    PubMedGoogle Scholar
  • 21 Menashi S, Aurosseau MH, Gozin D. et al. High levels of circulating thrombomodulin in human foetuses and children. Thromb Haemost 1999; 81: 906-9.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 22 Cvirn G, Gallistl S, Rehak G. et al. Elevated thrombin-forming capacity of tissue factor-activated cord compared with adult plasma. J Thromb Haemost 2003; 01: 1785-90.
    CrossrefPubMedGoogle Scholar
  • 23 Cvirn G, Gallistl S, Koestenberger M. et al. The anticoagulant action of recombinant human activated proteinC (rhAPC, Drotrecogin α activated): comparison between cord and adult plasma. Thromb Haemost 2004; 91: 912-8.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 24 Hemker HC, Giesen P, Dieri RA. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb 2003; 33: 4-15.
    CrossrefPubMedGoogle Scholar
  • 25 Hemker HC, Giesen PLA, Ramjee M. et al. The Thrombogram: Monitoring thrombin generation in platelet rich plasma. Thromb Haemost 2000; 83: 389-91.
    PubMedGoogle Scholar
  • 26 Vanschoonbeek K, Feijge MAH, van Kampen JW. et al. Initiating and potentiating role of platelets in tissue factor-induced thrombin generation in the presence of plasma: subject-dependent variation in thrombogram characteristics. J Thromb Haemost 2004; 02: 476-84.
    CrossrefPubMedGoogle Scholar
  • 27 Fernandez JA, Hackeng TM, Kojima K. et al. The carbohydrate moiety of factor V modulates inactivation by activated protein C. Blood 1997; 89: 4348-54.
    PubMedGoogle Scholar
  • 28 Gould WR, Silveira JR, Tracy PB. Unique in vivo modifications of coagulation factor V produce a physically and functionally distinct platelet-derived cofactor. J Biol Chem 2004; 279: 2383-93.
    CrossrefPubMedGoogle Scholar
  • 29 Smirnov MD, Esmon CT. Phoshpatidylethanolamine incorporation into vesicles selectively enhances factor Va inactivation by activated protein C. J Biol Chem 1994; 269: 816-9.
    PubMedGoogle Scholar
  • 30 Nicolaes GAF, Thomassen MCLGD, Tans G. et al. Effect of activated protein C on thrombin generation and on the thrombin potential in plasma of normal and APC-resistant individuals. Blood Coagul Fibrinol 1997; 08: 28-38.
    CrossrefPubMedGoogle Scholar
  • 31 Castoldi E, Brugge JM, Nicolaes GAF. et al. Impaired APC cofactor activity of factor V plays a major role in the APC resistance associated with the factor V Leiden (R506Q) and R2 (H1299R) mutations. Blood 2004; 103: 4173-9.
    CrossrefPubMedGoogle Scholar
  • 32 Zöller B, Holm J, Svensson P. et al. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
    Artikel in Thieme ConnectPubMedGoogle Scholar
  • 33 Simioni P, Scarano L, Gavasso S. et al. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-41.
    CrossrefPubMedGoogle Scholar
  • 34 Nowak-Göttl U, Vielhaber H. Elevated levels of soluble thrombomodulin in plasma from children with Arg 506 to Gln mutation in the factor V gene. Eur J Haematol 1997; 58: 51-5.
    PubMedGoogle Scholar
  • 35 Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999; 353: 1167-73.
    CrossrefPubMedGoogle Scholar
  • 36 Petäjä J, Manco-Johnson MJ. ProteinC pathway in infants and children. Semin Thromb Hemost 2003; 29: 349-61.
    Artikel in Thieme ConnectPubMedGoogle Scholar